Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359038 | 0.95 | NOD1 (0.59) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL137710 | 0.95 | NOD1 (0.59) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL12804895 | 0.95 | NOD1 (0.59) | NOD1PTGS1GSTK1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL9548427 | 0.93 | NOD1 (0.58) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL1217960 | 0.86 | NOD1 (0.55) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL1217963 | 0.86 | NOD1 (0.55) | NOD1PTGS1GSTK1KMT2APOLB | |
| Cysteamine SCHEMBL20768369 | 0.85 | PTGS1 (0.63) | NOD1PTGS1GSTK1KMT2AGLO1 | |
| SCHEMBL4577767 | 0.84 | PTGS1 (0.62) | NOD1PTGS1GSTK1GLO1FOLH1 | |
| SCHEMBL3664823 | 0.82 | NOD1 (0.60) | NOD1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL3664829 | 0.82 | NOD1 (0.60) | NOD1PTGS1GSTK1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111683684-B | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117599029-A | Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders | 硫创治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11786491-B2 | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230190683-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11612576-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220040127-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-11173135-B2 | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200268692-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | Prochimia Surfaces SP. Z.o.o. (PL) | 2020-08-27 | — | — | US | disclosed |
| US-20190070132-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| CN-109310653-A | Compositions for controlled release of cysteamine and systemic treatment of cysteamine-sensitive disorders | 硫创治疗公司 | 2019-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612576-B2 | Methods for the treatment of cysteamine sensitive disorders | CTH, CBS, SLC19A1 | NOD1 3751/4885PTGS1 557/4885GSTK1 86/4885 |
| US-20200268692-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | CTH, CBS, SLC19A1 | NOD1 3751/4885PTGS1 557/4885GSTK1 86/4885 |
| US-20230190683-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | CTH, CBS, SLC19A1 | NOD1 3751/4885PTGS1 557/4885GSTK1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.